Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): January 8,
2018
INNOVUS PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
|
8845 Rehco Road,
San Diego, CA
|
|
92122
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR
240.13e-4(c))
|
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Item 8.01 – Other Events
On January 8, 2018, the Company issued a press release announcing
that it had entered into an exclusive license and distribution
agreement with Acerus Pharmaceuticals Corporation
(“Acerus”), a Canadian company, for the distribution of
its UriVarx® product in Canada. Pursuant to the Acerus
agreement, Acerus shall provide Innovus with an up-front payment
and will be eligible to receive up to CAD$1.65 million in milestone
payments based on Acerus achieving certain sales targets and an
agreed-upon transfer price. Acerus also has minimum annual purchase
requirements for UriVarx® during the term of the
agreement.
The
full text of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K.
Item 9.01 -- Financial Statements and Exhibits
(d) Exhibits
|
Exhibit
Number
|
|
Description
|
|
|
|
Press release
issued January 8, 2018.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date: January 8, 2018
|
INNOVUS PHARMACEUTICALS,
INC.
|
|
|
|
|
|
By: /s/ Randy
Berholtz
Randy Berholtz
Executive Vice President,
Corporate Development
|
EXHIBIT
INDEX
|
Exhibit
Number
|
|
Description
|
|
|
|
Press release
issued January 8, 2018.
|